Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qishen Granules for Heart Failure with Preserved Ejection Fraction
NCT06377761Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Qishen Granules with Placebo (2 arms). Primary endpoint: Peak Oxygen Uptake at 90 days. Started May 2023; status: recruiting.
02
Drugs
Qishen Huoxue Granules
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06377761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06377761.